A 2 Part, Randomized, Double-Blind, Placebo-Controlled, Dose Titration, Safety, Tolerability, and Pharmacokinetics Study (Part 1) Followed by an Open-Label Efficacy and Safety Evaluation (Part 2) of SRP4053 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
Phase of Trial: Phase I/II
Latest Information Update: 13 Jun 2019
Price : $35 *
At a glance
- Drugs Golodirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Sponsors Sarepta Therapeutics
- 11 Jun 2019 Status changed from active, no longer recruiting to completed.
- 25 Mar 2019 This trial has been completed in France.
- 14 Mar 2019 Planned End Date changed from 29 Apr 2019 to 29 Mar 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History